Spondyloarthritis & psoriatic arthritis
Impact of clinical subtype and sex on first-line biologic therapy discontinuation in axial spondyloarthritis
Authors' conclusion
Nr-axSpA and female patients face a significantly higher risk of bDMARD discontinuation and shorter bDMARD survival. Although the combined effect of subtype and sex trended higher, it was not statistically significant.
Study context
- Population
- nr-axSpA and r-axSpA patients initiating TNF or IL-17 inhibitors as first biologic disease-modifying antirheumatic drug (bDMARD)64% discontinued
- Participants
- 469 participants
- Exposure
- nr-axSpA vs r-axSpA and female vs male sex, initiating TNF or IL-17 inhibitors
- Outcome
- Discontinuation of first bDMARD
Methodological detailsmodified Poisson regression, adjusted for baseline covariates, Kaplan-Meier analysis
- Modified Poisson regression
- Adjusted for baseline covariates
- Kaplan-Meier analysis
Main finding
As reported in the abstract
First bDMARD discontinuation
Relative risk (95% CI)
Nr-axSpAvs r-axSpA
1.80(1.26–2.59)
Femalevs Male
1.49(1.081–2.045)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Discontinuation, nr-axSpA femalesvs r-axSpA males | 2.30 (1.68–3.15) | P < 0.001 | |
| 0.20.5125Hazard ratio (log scale) |
Interaction between subtype and sex on discontinuation
- RERI (additive scale), 95% CI −0.78 to 1.75, not statistically significant
- 0.49
- RR ratio (multiplicative scale), 95% CI 0.55-2.03, not statistically significant
- 1.05
bDMARD survival over 20 years
- Significantly lower in nr-axSpA and female patients
Original publication
Impact of clinical subtype and sex on first-line biologic therapy discontinuation in axial spondyloarthritis. Ann Rheum Dis. Published 6 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →